MAXCYTE INC. - COMMON STOCK

MaxCyte Signs Strategic Platform License with Lyell Immunopharma

06 يوليو 2023 08:05:05 بحسب Nasdaq GlobeNewswire

MaxCyte to Participate in Upcoming Investor Conferences

01 يونيو 2023 16:05:00 بحسب Nasdaq GlobeNewswire

MaxCyte Reports First Quarter 2023 Financial Results and Updates Full Year 2023 Guidance

10 مايو 2023 16:05:01 بحسب Nasdaq GlobeNewswire

MaxCyte Signs Strategic Platform License with Walking Fish Therapeutics to Support the Development of its Innovative B Cell Platform

04 مايو 2023 08:05:53 بحسب Nasdaq GlobeNewswire

MaxCyte to Report First Quarter 2023 Financial Results on May 10, 2023

12 أبريل 2023 16:05:30 بحسب Nasdaq GlobeNewswire

MaxCyte Appoints Douglas Swirsky as Chief Financial Officer

27 مارس 2023 16:05:00 بحسب Nasdaq GlobeNewswire

MaxCyte Reports Fourth Quarter and Full Year 2022 Financial Results

15 مارس 2023 16:05:23 بحسب Nasdaq GlobeNewswire

MaxCyte Establishes New Scientific Advisory Board Comprised of Globally Recognized Experts in Cell Engineering Enabling Technology

08 مارس 2023 08:00:01 بحسب Nasdaq GlobeNewswire

MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Revenue Results and Provides 2023 Revenue Guidance

06 مارس 2023 16:05:00 بحسب Nasdaq GlobeNewswire

MaxCyte to Report Fourth Quarter and Full Year 2022 Financial Results on March 15, 2023 and Participate in Upcoming Investor Conferences

01 فبراير 2023 16:05:53 بحسب Nasdaq GlobeNewswire

MaxCyte Signs Strategic Platform License with Catamaran Bio to Support its CAR-NK Cell Therapy Programs

03 يناير 2023 16:05:00 بحسب Nasdaq GlobeNewswire

MaxCyte Signs Strategic Platform License with Curamys to Enable Cell & Gene Therapies for the Treatment of Rare Intractable Diseases

05 ديسمبر 2022 02:00:00 بحسب Nasdaq GlobeNewswire

MaxCyte Reports Third Quarter 2022 Financial Results

09 نوفمبر 2022 16:05:03 بحسب Nasdaq GlobeNewswire

MaxCyte to Participate in Upcoming Investor Conferences

02 نوفمبر 2022 08:05:00 بحسب Nasdaq GlobeNewswire

MaxCyte to Report Third Quarter 2022 Financial Results on November 9, 2022

12 أكتوبر 2022 08:00:01 بحسب Nasdaq GlobeNewswire

MaxCyte Signs Strategic Platform License with Vertex Pharmaceuticals to Advance CRISPR/Cas9-based Gene-editing Program

28 سبتمبر 2022 08:05:00 بحسب Nasdaq GlobeNewswire

MaxCyte Debuts New State-of-the-Art Headquarters in Maryland’s I-270 Biotech Corridor

21 سبتمبر 2022 08:05:00 بحسب Nasdaq GlobeNewswire

MaxCyte to Participate in Morgan Stanley 20th Annual Global Healthcare Conference

07 سبتمبر 2022 16:05:00 بحسب Nasdaq GlobeNewswire

MaxCyte Reports Second Quarter and Half-Year 2022 Financial Results

10 أغسطس 2022 16:05:01 بحسب Nasdaq GlobeNewswire

MaxCyte to Report Second Quarter 2022 Financial Results on August 10, 2022

15 يوليو 2022 08:00:00 بحسب Nasdaq GlobeNewswire